Insulet Corp. (NASDAQ: PODD) is a Healthcare company (Medical - Devices) with a market capitalization of $10.1B. The Maz Rating grades it against the other companies in its sector.
Insulet Corp.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $145.34, Insulet Corp. trades at 23.6x trailing earnings, 3.2x sales and 6.4x book value, with an EV/EBITDA of 15.2. Over the last twelve months it generated about $3.2B of revenue and $427M of net income. It runs a gross margin of 71.9%, an operating margin of 18.4% and a net margin of 13.4%. It shows return on equity of 29.5%, return on invested capital of 17.5% and a free cash flow yield of 2.6%. On the balance sheet: a debt-to-equity ratio of 0.61 and a current ratio of 2.51. Over the past 52 weeks the share price ranged from $126.40 to $354.88, with a beta of 1.06.
Insulet Corp. does not currently pay a dividend.
50 Wall Street analyst ratings cover the stock: 28 Buy, 20 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Insulet Corp. (PODD) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 9.70% / 30% · (Cash+Inv) / Mkt Cap (36m) 6.13% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 9.70% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.89% / 33% · Receivables / Mkt Cap (36m) 6.94% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 9.70% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.89% / 33.33% · Receivables / Mkt Cap (24m) 6.94% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 30.3% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 18.2% / 33.33% · Receivables / Avg Assets (4Q) 18.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 28.2% / 33.33% · (Cash+ST Inv) / Total Assets 17.1% / 33.33% · (Cash+Recv) / Total Assets 37.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Insulet Corp. (PODD) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. Insulet Corp. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Insulet Corp. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.